# Toripalimab Plus FLOT in Locally Advanced Gastric Cancer

> **NCT04891016** · PHASE2 · RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Chemotherapy
- Immune Checkpoint Inhibitor
- Locally Advanced Gastric Carcinoma

## Interventions

- **DRUG:** FLOT combined with toripalimab

## Key facts

- **NCT ID:** NCT04891016
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-25
- **Primary completion:** 2025-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04891016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04891016, "Toripalimab Plus FLOT in Locally Advanced Gastric Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04891016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*